Frontiers Case report: Short-term eculizumab use in atypical HUS

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies - ScienceDirect

PDF) Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses

Frontiers Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing

PDF) The use of eculizumab in gemcitabine induced thrombotic microangiopathy

Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome - ScienceDirect

Frontiers Case report: Novel FHR2 variants in atypical Hemolytic Uremic Syndrome: A case study of a translational medicine approach in renal transplantation

Frontiers Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome

Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome - ScienceDirect

PDF) Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity

Eculizumab for Atypical Hemolytic–Uremic Syndrome

PDF] Atypical hemolytic uremic syndrome: a syndrome in need of clarity

Frontiers Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study - ScienceDirect

atypical hemolytic uremic syndrome - List of Frontiers' open access articles